GLUE
NASDAQMonte Rosa Therapeutics Inc.
News25/Ratings11
News · 26 weeks61-17%
2026-03-012026-08-23
Mix3390d
- Insider22(67%)
- Other7(21%)
- SEC Filings4(12%)
Latest news
25 items- PRMonte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate CancerStudy will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed in MODeFIRe-1 (clinicaltrials.gov identifier NCT07745361), a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor (AR) inhibitor, in patients w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- SECSEC Form 10-Q filed by Monte Rosa Therapeutics Inc.10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECMonte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- PRMonte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesCompleted enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk and cardiometabolic syndrome in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 MODeFIRe-1 Phase 2 study of MRT-2359 activated, in combination with apalutamide in metastatic castration-resistant prostate cancer patients (mCRPC) with androgen receptor (AR) mutations Phase 2a/b clinical trial for VAV1-directed MGD MRT-6160 (DDY391) act
- INSIDERPresident & CEO Warmuth Markus sold $220,219 worth of shares (9,500 units at $23.18), decreasing direct ownership by 2% to 585,038 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Operating Officer Champoux Jennifer exercised 4,351 shares at a strike of $3.98 and sold $101,730 worth of shares (4,351 units at $23.38) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- INSIDERChief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $139,849 worth of shares (6,000 units at $23.31) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERDirector Behbahani Ali disposed of 1,015,000 shares and acquired 15,000 shares (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- PRMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 18,025 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $24.02 as reported by Nasdaq on July 1, the effective date of the grant or the "Grant Date", which will v
- INSIDERChief Medical Officer Janku Filip exercised 5,407 shares at a strike of $13.41 and sold $132,472 worth of shares (5,407 units at $24.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Medical Officer Janku Filip exercised 6,000 shares at a strike of $7.56 and sold $137,700 worth of shares (6,000 units at $22.95) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERDirector Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $231,100 worth of shares (10,000 units at $23.11) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SECSEC Form 144 filed by Monte Rosa Therapeutics Inc.144 - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- INSIDERChief Medical Officer Janku Filip exercised 36,000 shares at a strike of $7.56 and sold $882,203 worth of shares (41,845 units at $21.08) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 59,992 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $60,000 worth of shares (3,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Operating Officer Champoux Jennifer sold $43,500 worth of shares (2,175 units at $20.00) as part of a pre-agreed trading plan and exercised 2,175 shares at a strike of $3.98 (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $57,000 worth of shares (3,000 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 4 filed by Director Behbahani Ali4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 4 filed by Director Schiff Andrew N4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 4 filed by Director Manning Anthony M.4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 4 filed by Director Skvarka Jan4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
GLUE FAQ
6 questionsWhere does GLUE stock trade?
Monte Rosa Therapeutics Inc. (GLUE) is listed on NASDAQ.What sector and industry is GLUE in?
Monte Rosa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Monte Rosa Therapeutics Inc. go public?
Monte Rosa Therapeutics Inc. (GLUE) completed its IPO in 2021.What are analysts saying about GLUE?
Monte Rosa Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $1100.00 price target on 2024-12-19. Recent price targets range from $1100.00 to $2200.00.What companies are similar to GLUE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare GLUE side-by-side with any of them on Quantisnow.How can I track GLUE on Quantisnow?
Quantisnow aggregates Monte Rosa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLUE to receive live email and push alerts on every new disclosure.